Anti program death-1/anti program death-ligand 1 in digestive cancers

doi:10.4251/wjgo.v7.i8.95

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11096)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

741

WORD

431

HTML

4765

Figures (1-3)

239

Tables (1-1)

225

Sum=6401

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

569

Download

1634

Sum=2203

Publishing Process of This Article

Item

Count

Browse

1123

Download

1369

Sum=2492

Aug 15, 2015 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (41)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastrointest Oncol. Aug 15, 2015; 7(8): 95-101
Published online Aug 15, 2015. doi: 10.4251/wjgo.v7.i8.95

Table 1 Ongoing anti program death-1 or anti program death-ligand 1 monoclonal antibodies clinical trials in digestive cancers

Monoclonal antibody	Antibody description	Association	Tumors
MPDL3280A	Anti-PD-L1 Engineered	MODUL trial: Phase III biomarker driven maintenance therapy	Metastatic colorectal cancer
	Human
	IgG1¹
Medi 4736	Anti-PD-L1	None	Immunological subsets of advanced colorectal cancer
	Engineered
	Human
	IgG1¹
Nivolumab	Anti-PD-1	Nab-paclitaxel +/- Gemcitabine	Pancreatic cancer
	Fully human
	IgG4²
		GVAX pancreas vaccine + CRS-207	Pancreatic cancer
		None	Squamous cell carcinoma of the anal canal
		Ipilimumab	Recurrent and metastatic colon cancer
		None	Hepatocellular carcinoma
		None	Advanced or recurrent gastric cancer
Pembrolizumab	Anti-PD-1	None	Resectable or borderline resectable pancreas cancer
	Humanized
	IgG4²
		None	Advanced gastro-intestinal cancers
		None	Metastastic colorectal cancer with and without microsatellite instability

¹Engineered Fc domain prevent antibody dependent cell mediated cytotoxicity (ADCC);

²IgG4 antibody do not induce ADCC. PD-1: Program death-1; PD-L1: Program death-ligand 1; Ig: Immunoglobulin; GVAX: Granulocyte-macrophage colony-stimulating factor–secreting allogeneic pancreatic tumor cells, induces T-cell immunity to cancer antigens, including mesothelin; CRS-207: Live-attenuated L monocytogenes-expressing mesothelin.

Citation: Guillebon E, Roussille P, Frouin E, Tougeron D. Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol 2015; 7(8): 95-101
URL: https://www.wjgnet.com/1948-5204/full/v7/i8/95.htm
DOI: https://dx.doi.org/10.4251/wjgo.v7.i8.95